Soleno Therapeutics
SLNO
SLNO was delisted on the 15th of May, 2026.
12 hedge funds and large institutions have $7.13M invested in Soleno Therapeutics in 2016 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
9% more funds holding
Funds holding: 11 → 12 (+1)
0.73% more ownership
Funds ownership: 0% → 0.73% (+0.73%)
5% less capital invested
Capital invested by funds: $7.5M → $7.13M (-$363K)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$328K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$231K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$14.1K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$4.99K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.04K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$61.6K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$23K |
| 3 |
BG
Bollard Group
Boston,
Massachusetts
|
-$19.2K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
-$10K |
| 5 |
Goldman Sachs
New York
|
-$2.15K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VC
1
Vivo Capital
Palo Alto,
California
| $6.04M | – | – | – |
|
|
BG
2
Bollard Group
Boston,
Massachusetts
| $310K | -$19.2K | -277 | -5% |
|
|
AFM
3
Anson Funds Management
Dallas,
Texas
| $288K | +$328K | +4,740 | New |
|
|
4
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $202K | +$231K | +3,333 | New |
|
|
SM
5
Sabby Management
Miami Beach,
Florida
| $145K | -$61.6K | -889 | -27% |
|
|
BIT
6
BlackRock Institutional Trust
San Francisco,
California
| $61K | – | – | – |
|
|
7
Vanguard Group
Malvern,
Pennsylvania
| $50K | +$1.04K | +15 | +2% |
|
|
8
Goldman Sachs
New York
| $19K | -$2.15K | -31 | -9% |
|
|
TSS
9
Two Sigma Securities
New York
| $12K | +$14.1K | +203 | New |
|
|
10
UBS Group
Zurich,
Switzerland
| $5K | +$4.99K | +72 | +2,400% |
|
|
BFA
11
BlackRock Fund Advisors
San Francisco,
California
| $1K | +$485 | +7 | +50% |
|
|
12
Citadel Advisors
Miami,
Florida
| – | -$23K | -317 | Closed |
|
|
VKH
13
Virtu KCG Holdings
New York
| – | -$10K | -151 | Closed |
|
14
Bank of America
Charlotte,
North Carolina
| – | -$1.11K | -16 | -94% |
|
SLNO Hedge Fund Activity: Q4 2016 in Review
12 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics (SLNO) for Q4 2016, worth a combined $7.13M — down 4.8% from $7.5M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new SLNO positions and 2 closed out — a net gain of 1 holder — while 3 added to existing stakes and 4 trimmed.
The largest buyer was Anson Funds Management, opening a new position worth an estimated $328K. The largest seller was Sabby Management, cutting an estimated $61.6K.
- 12 institutional investors held Soleno Therapeutics (SLNO) as of Q4 2016, up from 11 in Q3 2016.
- Funds reported $7.13M of Soleno Therapeutics stock for Q4 2016, down 4.8% quarter-over-quarter.
- 3 funds opened new Soleno Therapeutics positions in Q4 2016 and 2 closed out, a net change of +1 holder.
- The largest Soleno Therapeutics buyer in Q4 2016 was Anson Funds Management, an estimated $328K added.
- The largest Soleno Therapeutics seller in Q4 2016 was Sabby Management, an estimated $61.6K sold.
Based on aggregated 13F filings for Q4 2016.